Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Chromosomal analysis or the study of genetic differences in patients previously untreated
with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It
may also improve the ability to predict the course of disease and the selection of therapy.
Institutions must have either an Alliance-approved cytogeneticist or an agreement from an
Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The
Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical
Trials in Oncology website.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.